

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Doxazosin (mesylate)

Item No. 18633

CAS Registry No.: 77883-43-3

Formal Name: [4-(4-amino-6,7-dimethoxy-

> 2-quinazolinyl)-1-piperazinyl] (2,3-dihydro-1,4-benzodioxin-2-yl)methanone, monomethanesulfonate

Synonym: UK 33274-27


MF: $C_{23}H_{25}N_5O_5 \bullet CH_3SO_3H$

FW: 547.6 **Purity:** ≥98%

 λ_{max} : 247, 330 nm UV/Vis.: A crystalline solid Supplied as:

-20°C Storage: ≥2 years Stability:

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Doxazosin (mesylate) is supplied as a crystalline solid. A stock solution may be made by dissolving the doxazosin (mesylate) in the solvent of choice. Doxazosin (mesylate) is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of doxazosin (mesylate) in these solvents is approximately 2 and 0.5 mg/ml, respectively.

Doxazosin (mesylate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, doxazosin (mesylate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Doxazosin (mesylate) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Doxazosin is a non-selective antagonist of α_1 -adrenergic receptors (α_1 -ARs; K_i s = 3.16, 1, and 3.98 nM for α_{1A}^{-} , α_{1B}^{-} , and α_{1D}^{-} ARs, respectively). It inhibits norepinephrine-induced contractions in isolated rat aorta rings and human prostate strips with pA_2 values of 8.8 and 8.2, respectively. Doxazosin inhibits phenylephrine-induced increases in blood pressure and prostatic pressure in anesthetized dogs $(pA_2 = 7.5)$ for both). Formulations containing doxazosin have been used in the treatment of benign prostatic hyperplasia and hypertension.

Reference

1. Jardin, A., Bensadoun, H., Delauche-Cavallier, M.C., et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337, 1457-1461 (1991).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 07/07/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM